Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

ZBIO vs TWST: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

TWST Wins Head-to-Head Institutional Verdict (5–1 across 6 Pillars · 5–3 Matrix Metrics)

TWST Overall Winner 6-Pillar Tally: ZBIO 1 – 5 TWST Matrix Metrics: ZBIO 3 – 5 TWST

As of Nov 16, 2026, Twist Bioscience Corporation (TWST) is the stronger overall head-to-head candidate over Zenas BioPharma, Inc. (ZBIO) in the Tradestie Institutional Equity Comparison Engine, winning 5–3 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). ZBIO carries a Unified Composite Score of 49.4/100 (HOLD) at $27.93 (N/M Forward P/E, -2747.5% operating margin), whereas TWST carries 51.7/100 (HOLD) at $105.04 (N/M Forward P/E, -31.9% operating margin).

  • Technical & Structure Timing Caution: ZBIO is currently in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 49.0); meanwhile TWST trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 36.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About ZBIO vs TWST
ZBIO NASDAQ
Zenas BioPharma, Inc. Common Stock
Pharmaceutical Preparations
$27.93
-0.29% 1D
Market Cap $1.9B
TTM Revenue $11M
Forward P/E N/M
Beta / 30D Vol 1.16β · 59% Vol
Unified Composite Score
49.4 / 100 HOLD
Tech 44.0 Fund 53.0 Flow 69.0 Mom 50.0
Weinstein Technical Phase Distribution · Trim / tighten stop
Price near a flattening SMA50 (slope -5.2%) with fading momentum, RSI 49
RSI-14: 49.0 · SMA20: $27.99 · SMA50: $28.48
TWST NASDAQ Head-to-Head Winner
Twist Bioscience Corporation Common Stock
Biological Products, (No Disgnostic Substances)
$105.04
-5.88% 1D
Market Cap $7.6B
TTM Revenue $432M
Forward P/E N/M
Beta / 30D Vol 3.13β · 126% Vol
Unified Composite Score
51.7 / 100 HOLD
Tech 40.0 Fund 56.0 Flow 68.0 Mom 64.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 36
RSI-14: 36.1 · SMA20: $137.35 · SMA50: $149.85

6-Pillar Scorecard Institutional Category Breakdown (ZBIO 1 – 5 TWST)

Columns: Metric · ZBIO · TWST
1. Valuation Multiples TWST
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue N/M 17.5x
2. Growth & Scale TWST
Revenue Growth (YoY) -100.0% +23.2%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $11M $432M
Market Cap $1.9B $7.6B
3. Profitability & Quality TWST
Gross Margin N/A 52.0%
Operating Margin -2747.5% -31.9%
Net Profit Margin 0.0% -31.7%
Return on Equity (ROE) -265.1% -29.6%
4. Balance Sheet & Cash Flow TWST
Cash Generation (TTM) -$273M -$115M EBITDA
Cash Flow Margin N/A -26.7% EBITDA Mgn
Net Cash / Leverage $177M Net Cash $7.11 Book/Sh · -29.6% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning ZBIO
Options Structure Phase CONSOLIDATION CONSOLIDATION
Current IV / %ile 95.3% (12th %ile) 93.2% (18th %ile)
Put/Call OI Skew N/A 1.04x (Balanced)
OBV Trend / Tech Phase ACCUMULATION · Distribution DISTRIBUTION · Neutral
6. R&D & Supply-Chain Moat TWST
OpEx & R&D Intensity N/A 83.9% of Rev ($362M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: ZBIO (3) vs TWST (5)
Institutional Metric ZBIO TWST Criterion Row Edge
Market Capitalization
Scale
$1.9B $7.6B Larger Scale TWST
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
-100.0% +23.2% Higher Growth TWST
Operating Margin (TTM)
Profitability
-2747.5% -31.9% Higher Margin TWST
Net Profit Margin
Profitability
0.0% -31.7% Higher Margin ZBIO
Return on Equity (ROE)
Capital Efficiency
-265.1% -29.6% Higher ROE TWST
52-Week Range Position
Momentum
46% ($14–$45) 42% ($23–$220) Stronger Trend ZBIO
Beta / 30D Volatility
Risk Regime
1.16β · 59% Vol 3.13β · 126% Vol Lower Realized Risk ZBIO
Unified Institutional Score
Composite Signal
49.4 / 100 (HOLD) 51.7 / 100 (HOLD) Higher Composite TWST
Trailing 12M Revenue (USD)
Operating Scale
$11M $432M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A 52.0% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · 17.5x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$273M ($177M Net Cash) -$115M EBITDA ($7.11 Book/Sh · -29.6% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon ZBIO +33.31 pp
ZBIO: +12.44% · TWST: -20.87%
3M Horizon TWST +2.94 pp
ZBIO: -12.47% · TWST: -9.53%
6M Horizon TWST +45.8 pp
ZBIO: +65.17% · TWST: +110.97%
1Y Horizon TWST +272.98 pp
ZBIO: -21.68% · TWST: +251.3%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period ZBIO Revenue TWST Revenue ZBIO Op. Margin TWST Op. Margin Margin Leader
FY2018 N/A $30M N/A -277.5% TWST
FY2019 N/A $50M N/A -200.1% TWST
FY2020 N/A $90M N/A -155.5% TWST
FY2021 N/A $130M N/A -115.4% TWST
FY2022 N/A $200M N/A -115.3% TWST
FY2023 $50M $250M -74.3% -88.6% ZBIO
FY2024 $10M $310M -3277.8% -70.6% TWST
FY2025 $10M $380M -3830.6% -36.2% TWST

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
ZBIO CONSOLIDATION
58d in phase · OBV ACCUMULATION
Current IV 95.3%
IV Percentile 12th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow ACCUMULATION
Exact ZBIO Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
TWST CONSOLIDATION
69d in phase · OBV DISTRIBUTION
Current IV 93.2%
IV Percentile 18th %ile
Put/Call OI Skew 1.04x (Balanced)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow DISTRIBUTION
Exact TWST Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
ZBIO Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $1.9B market capitalization and -2747.5% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
TWST Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $7.6B market capitalization and -31.9% operating margin.
OpEx & R&D Reinvestment 83.9% of Rev ($362M)
90D Engineering Disclosures 0 Published · Spatial Genomics

Investor FAQ ZBIO vs TWST Key Questions & Quantitative Answers

As of Nov 16, 2026, Twist Bioscience Corporation (TWST) is the stronger overall head-to-head candidate over Zenas BioPharma, Inc. (ZBIO) in the Tradestie Institutional Equity Comparison Engine, winning 5–3 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). ZBIO carries a Unified Composite Score of 49.4/100 (HOLD) at $27.93 (N/M Forward P/E, -2747.5% operating margin), whereas TWST carries 51.7/100 (HOLD) at $105.04 (N/M Forward P/E, -31.9% operating margin). Technical & Structure Timing Caution: ZBIO is currently in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 49.0); meanwhile TWST trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 36.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

TWST leads the Growth & Scale pillar: ZBIO posts -100.0% YoY revenue growth and +0.0% YoY earnings growth on $11M TTM revenue (N/A gross margin, -2747.5% operating margin), compared with TWST at +23.2% YoY revenue growth and +0.0% YoY earnings growth on $432M TTM revenue (52.0% gross margin, -31.9% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), ZBIO cumulative revenue shifted -80.0% while TWST shifted +1166.7%. In operating R&D and SG&A reinvestment, ZBIO deploys N/A (0 90-day corporate R&D disclosures) versus 83.9% of Rev ($362M) (0 disclosures) for TWST.

TWST screens cheaper on headline valuation multiples. ZBIO trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas TWST trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 17.5x EV/Revenue (-26.7% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ZBIO (-265.1% ROE) versus TWST (-29.6% ROE) capital efficiency.

In options market volatility and institutional positioning, ZBIO carries 95.3% implied volatility (12th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a CONSOLIDATION options structure phase (1.16β · 59% Vol realized risk). By comparison, TWST carries 93.2% implied volatility (18th %ile, Compressed (<25th %ile)), a 1.04x (Balanced) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (3.13β · 126% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.